Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs? / Herbild, Louise; Andersen, Stig Ejdrup; Werge, Thomas; Rasmussen, Henrik Berg; Jürgens, Gesche.

In: Basic & Clinical Pharmacology & Toxicology, Vol. 113, No. 4, 04.06.2013, p. 266–272.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Herbild, L, Andersen, SE, Werge, T, Rasmussen, HB & Jürgens, G 2013, 'Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?', Basic & Clinical Pharmacology & Toxicology, vol. 113, no. 4, pp. 266–272. https://doi.org/10.1111/bcpt.12093

APA

Herbild, L., Andersen, S. E., Werge, T., Rasmussen, H. B., & Jürgens, G. (2013). Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs? Basic & Clinical Pharmacology & Toxicology, 113(4), 266–272. https://doi.org/10.1111/bcpt.12093

Vancouver

Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G. Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs? Basic & Clinical Pharmacology & Toxicology. 2013 Jun 4;113(4):266–272. https://doi.org/10.1111/bcpt.12093

Author

Herbild, Louise ; Andersen, Stig Ejdrup ; Werge, Thomas ; Rasmussen, Henrik Berg ; Jürgens, Gesche. / Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?. In: Basic & Clinical Pharmacology & Toxicology. 2013 ; Vol. 113, No. 4. pp. 266–272.

Bibtex

@article{4eafd56786534ab3aadb95952d4d10ca,
title = "Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?",
abstract = "The effect of pharmacogenetic testing for CYP450 2D6 and 2C19 on treatment costs have not yet been documented. This study used Danish patient registers to calculate health care costs of treating patients with diagnoses within the schizophrenic spectrum for one year with or without pharmacogenetic testing for polymorphisms in the genes for the CYP2D6 and CYP2C19 enzymes. In a randomized, controlled trial, stratified with respect to metabolizer genotype, 104 patients were assigned to treatment based on pharmacogenetic testing and 103 patients to treatment as usual. Random exclusion of extensive and intermediate metabolizers was used to increase the frequency of extreme metabolizers (poor metabolizers and ultrarapid metabolizers for CYP2D6) to 20% in both groups. This article is protected by copyright. All rights reserved.",
author = "Louise Herbild and Andersen, {Stig Ejdrup} and Thomas Werge and Rasmussen, {Henrik Berg} and Gesche J{\"u}rgens",
note = "This article is protected by copyright. All rights reserved.",
year = "2013",
month = jun,
day = "4",
doi = "10.1111/bcpt.12093",
language = "English",
volume = "113",
pages = "266–272",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?

AU - Herbild, Louise

AU - Andersen, Stig Ejdrup

AU - Werge, Thomas

AU - Rasmussen, Henrik Berg

AU - Jürgens, Gesche

N1 - This article is protected by copyright. All rights reserved.

PY - 2013/6/4

Y1 - 2013/6/4

N2 - The effect of pharmacogenetic testing for CYP450 2D6 and 2C19 on treatment costs have not yet been documented. This study used Danish patient registers to calculate health care costs of treating patients with diagnoses within the schizophrenic spectrum for one year with or without pharmacogenetic testing for polymorphisms in the genes for the CYP2D6 and CYP2C19 enzymes. In a randomized, controlled trial, stratified with respect to metabolizer genotype, 104 patients were assigned to treatment based on pharmacogenetic testing and 103 patients to treatment as usual. Random exclusion of extensive and intermediate metabolizers was used to increase the frequency of extreme metabolizers (poor metabolizers and ultrarapid metabolizers for CYP2D6) to 20% in both groups. This article is protected by copyright. All rights reserved.

AB - The effect of pharmacogenetic testing for CYP450 2D6 and 2C19 on treatment costs have not yet been documented. This study used Danish patient registers to calculate health care costs of treating patients with diagnoses within the schizophrenic spectrum for one year with or without pharmacogenetic testing for polymorphisms in the genes for the CYP2D6 and CYP2C19 enzymes. In a randomized, controlled trial, stratified with respect to metabolizer genotype, 104 patients were assigned to treatment based on pharmacogenetic testing and 103 patients to treatment as usual. Random exclusion of extensive and intermediate metabolizers was used to increase the frequency of extreme metabolizers (poor metabolizers and ultrarapid metabolizers for CYP2D6) to 20% in both groups. This article is protected by copyright. All rights reserved.

U2 - 10.1111/bcpt.12093

DO - 10.1111/bcpt.12093

M3 - Journal article

C2 - 23731498

VL - 113

SP - 266

EP - 272

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 4

ER -

ID: 48609690